Get the Stockscreener App
23.76
2.41%
0.56
After Hours:
22.51
-1.25
-5.26%
Rapport Therapeutics Inc stock is traded at $23.76, with a volume of 1.65M.
It is up +2.41% in the last 24 hours and up +52.90% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$23.20
Open:
$24.25
24h Volume:
1.65M
Relative Volume:
3.02
Market Cap:
$867.19M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+65.46%
1M Performance:
+52.90%
6M Performance:
+137.36%
1Y Performance:
+25.65%
1-Day Range:
$22.73
$25.14
1-Week Range:
$22.06
$42.27
52-Week Range:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
23.76 | 817.55M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
Rapport Therapeutics Inc Stock (RAPP) Latest News
Rapport Therapeutics (NASDAQ:RAPP) Reaches New 1-Year High Following Analyst Upgrade - MarketBeat
Cheryl Gault Sells 5,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal - Zacks Investment Research
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownHere's Why - MarketBeat
Rapport stock moved to Buy at Goldman Sachs (RAPP:NASDAQ) - Seeking Alpha
Rapport Therapeutics to Participate in TD Cowen's 5th - GlobeNewswire
Nuveen LLC Makes New Investment in Rapport Therapeutics, Inc. $RAPP - MarketBeat
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit - The Manila Times
Rapport Therapeutics Announces Public Offering Agreement - MSN
Rapport Therapeutics (NASDAQ:RAPP) Sees Strong Trading Volume After Analyst Upgrade - MarketBeat
Rapport Therapeutics price target raised to $34 from $31 at H.C. Wainwright - MSN
Rapport Therapeutics Target of Unusually Large Options Trading (NASDAQ:RAPP) - MarketBeat
| MarketBeat - MarketBeat
Rapport Therapeutics says Phase 2a trial of RAP-219 met primary endpoint - MSN
HC Wainwright Forecasts Strong Price Appreciation for Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics plans to hold end-of-Phase 2 meeting with FDA in Q4 - MSN
Rapport Therapeutics Prices $250 Million Common Stock Offering - MarketScreener
Rapport Therapeutics prices $250 million public offering at $26 per share - Investing.com India
Rapport Therapeutics prices $250 million public offering at $26 per share By Investing.com - Investing.com South Africa
Rapport Announces Pricing of Public Offering of Common Stock - Yahoo Finance
Rapport says public offering of 9.6 million shares of its common stock at a price of $26.00 per share - MarketScreener
$250 Million Stock Offering: Neurological Drug Developer Rapport Therapeutics Raises Growth Capital - Stock Titan
Rapport Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock - Quiver Quantitative
RAPPRapport Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Rapport Announces Pricing of Public Offering of Common Stock - Benzinga
Top chart patterns to watch in Rapport Therapeutics Inc.2025 Volatility Report & Safe Entry Momentum Tips - Newser
Earnings visualization tools for Rapport Therapeutics Inc.Weekly Stock Report & High Return Trade Guides - Newser
Rapport Therapeutics Terminates Common Stock Prospectus - MSN
Rapport’s precision synaptic targeting and innovative trial design deliver in Phase II - biocentury.com
Rapport rockets on positive trial data for RAP219 - The Pharma Letter
Rapport Therapeutics Inc. stock outlook for YEARInsider Buying & Fast Gain Stock Trading Tips - Newser
Will Rapport Therapeutics Inc. bounce back from current supportWeekly Trend Recap & Accurate Technical Buy Alerts - Newser
Will Rapport Therapeutics Inc. continue its uptrendJuly 2025 Institutional & Intraday High Probability Alerts - Newser
What MACD and RSI say about Rapport Therapeutics Inc.Market Volume Report & Weekly High Return Stock Forecasts - Newser
How to integrate Rapport Therapeutics Inc. into portfolio analysis toolsGap Up & Risk Adjusted Swing Trade Ideas - Newser
What machine learning models say about Rapport Therapeutics Inc.2025 Key Lessons & Technical Pattern Based Signals - Newser
Evaluating Rapport Therapeutics Inc. with trendline analysisMarket Trend Review & High Conviction Buy Zone Picks - Newser
Is it time to cut losses on Rapport Therapeutics Inc.Portfolio Profit Report & Precise Swing Trade Alerts - Newser
What MACD signals say about Rapport Therapeutics Inc.Trade Ideas & Real-Time Price Movement Reports - Newser
Rapport Therapeutics launches $250 million public stock offering - Investing.com
How to use a screener to detect Rapport Therapeutics Inc. breakoutsProfit Target & Trade Opportunity Analysis - Newser
Biotech And Small-Cap Stocks Stole The Show With Massive Moves - Finimize
Using AI based signals to follow Rapport Therapeutics Inc.July 2025 Market Mood & Accurate Intraday Trade Tips - Newser
Rapport Therapeutics (NASDAQ:RAPP) Given New $34.00 Price Target at HC Wainwright - Defense World
Building trade automation scripts for Rapport Therapeutics Inc.2025 Market Trends & Technical Confirmation Trade Alerts - Newser
Rapport Therapeutics (NASDAQ:RAPP) Hits New 12-Month High After Analyst Upgrade - Defense World
Measuring Rapport Therapeutics Inc.’s beta against major indicesQuarterly Market Review & Weekly Return Optimization Plans - Newser
Rapport soars on phase II RAP-219 data in focal onset seizures - BioWorld MedTech
Will RAPP’s Momentum Continue? - timothysykes.com
Rapport Therapeutics launches $250 million public stock offering By Investing.com - Investing.com Canada
Rapport Moves Closer Toward Blockbuster Epilepsy Opportunity - insights.citeline.com
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):